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Abstract
Epitopes shared by the vaccinia and variola viruses underlie the protective effect of vaccinia
immunization against variola infection. We set out to identify a subset of cross-reactive epitopes
using bioinformatics and immunological methods. Putative T-cell epitopes were computationally
predicted from highly conserved open reading frames from seven complete vaccinia and variola
genomes using EpiMatrix. Over 100 epitopes bearing low human sequence homology were selected
and assessed in HLA binding assays and in T-cell antigenicity measurements using PBMCs isolated
from Dryvax-immunized subjects. Experimental validation of computational predictions illustrates
the potential for immunoinformatics methods to identify candidate immunogens for a new, safer
smallpox vaccine.
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1. Introduction
Over 200 years ago, Edward Jenner developed vaccination against variola virus using the
related poxvirus vaccinia, enabling a worldwide effort that culminated in the eradication of
smallpox 1979. In wake of the September 11, 2001 terror attacks, fears of deliberate
dissemination of variola in an unprotected world population prompted the United States
government to stockpile vaccine for the civilian population. Licensed smallpox vaccines, such
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as Dryvax (Wyeth) and WetVax (Aventis Pasteur) effectively protect against infection but are
contraindicated for about 20% of the US population because they are associated with a broad
range of adverse events. For example, dermal complications including vaccinia necrosum, a
progressive skin condition with case-fatality rates of 75% to 100% among persons with cellular
immunodeficiency, were observed during the global campaign to eradicate smallpox [1].
Eczema vaccinatum, a complication among eczema patients, was associated with case-fatality
rates of up to 10% overall and 30% to 40% in children younger than two years of age. Moreover,
inadvertent inoculation may result in wider spread when vaccinia is transferred from the
vaccination site to another location on the vaccinee or to another person [2]. As a result,
smallpox vaccination is contraindicated in persons who have eczema, active acute, chronic, or
exfoliative skin conditions that disrupt the epidermis, HIV/AIDS, autoimmune conditions,
cancer, radiation treatment, or immunodeficiencies.
We set out to design a safer smallpox vaccine that will provide protection to a greater proportion
of the US population. Because epitopes provide the minimal essential information needed to
trigger a protective immune response, epitope-driven vaccines represent a logical approach to
vaccine development that obviates the risks inherent in live vaccines. Our approach to
discovering T-cell epitopes is based on the advent of fully sequenced poxvirus genomes
coupled with the availability of immunoinformatics tools that can rapidly identify potentially
immunogenic and protective poxvirus sequences. In light of the well known fact that vaccinia
immunization protects against variola infection, our studies focused on the subset of epitopes
that are common to both poxvirus strains (Figure 1). Here, we report the results of the first
steps in the vaccine design process whereby computationally identified epitopes were validated
in vitro and ex vivo in order to select epitopes to be later tested as a prototype vaccine in a
human leukocyte antigen (HLA) transgenic mouse model.
2. Materials and Methods
2.1. Immunoinformatics
Seven complete poxvirus genomes were downloaded from GenBank: four vaccinia strains
(Tian Tian, Accession AF095689; Western Reserve, Accession AY243312; Copenhagen,
Accession M35027; Ankara, Accession U94848) and three variola (Variola major, strain India
1967, Accession X69198; Variola major, strain Bangladesh 1975, Accession L22597; Variola
minor, strain Garcia 1966, Accession Y16780).
EpiMatrix, a matrix-based epitope mapping algorithm, was used to identify Class I and II HLA
epitopes in vaccinia and variola open reading frame (ORF) sequences [3,4,5]. For Class I
epitope identification, 9-mer and 10-mer sequences were scored for potential binding to six
supertype Class I alleles (A*0101, A*0201, A*0301, A*2402, B*0702 and B*4403 alleles)
that cover >90% of humans in five major human population groups [6]. For Class II epitope
identification, potential binding of 9-mer sequences was scored for eight archetypical Class II
alleles (DRB1*0101, *0301, *0401, *0701, *1101, *1301 and *1501) that are expected to
cover over 95% of any given human population [7]. EpiMatrix raw scores were normalized
with respect to a score distribution derived from a very large set of randomly generated peptide
sequences. The resulting “Z” scores are normally distributed and directly comparable across
alleles. Any peptide scoring above 1.64 on the “Z” scale (approximately the top 5% of any
given peptide set) has a significant chance of binding to the MHC molecule for which it was
predicted. Peptides scoring above 2.32 on the scale (the top 1%) are extremely likely to bind;
most well known T-cell epitopes fall within this range of scores.
Vaccinia/variola ORF and epitope homology were evaluated using Conservatrix, a sequence
alignment algorithm that searches a dataset for matching segments. Criteria for conservation
significance were application dependent and are described in the Results section. Epitopes were
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evaluated for homology with human sequences using the BLAST algorithm [8]. Clusters with
no more than 7 matches per 9-mer frame were selected for further study.
For ORFs conserved across all vaccinia/variola strains, HLA Class II epitopes were further
analyzed for clustering and among all other ORFs, extended immunogenic consensus
sequences (ICS) were developed. Regions of HLA Class II epitope density were discovered
using ClustiMer, an algorithm that uses a statistical function to identify sequences which
contain more predicted epitopes than would be found by chance alone [9,10]. Clusters whose
sum of significant EpiMatrix Z-scores exceeded a value of 10 after subtracting the expected
sum of scores for a random sequence of equal length, were considered for further study. ICS
were built by EpiAssembler, an algorithm that maximizes epitope density in a 20-25 amino
acid stretch by assembling potentially immunogenic 9-mers to be identically positioned as they
are in their native protein sequences [11].
2.2. Peptide Synthesis
Peptides were manufactured using 9-fluoronylmethoxycarbonyl (Fmoc) chemistry by SynPep
(Dublin, CA) and by New England Peptide (Gardner, MA). Peptides were purified to >80%
as ascertained by analytical reversed phase HPLC. Peptide mass was confirmed by MALDI-
TOF mass spectrometry.
2.3. HLA Binding Assays
2.3.1. Class I Assay—Class I A2 and B7 peptides were assayed for HLA binding using a
quantitative “sandwich” ELISA, as described previously [12]. HLA class I A2 or B7 molecules
were incubated at a concentration of ∼2 nM together with 25 nM human β2 microglobulin
(β2m) and an increasing concentration of test peptides at 18°C for 48 h. HLA molecules were
then captured on a 96-well plate coated with the pan-specific anti-human MHC class I mouse
monoclonal antibody W6/32, and HLA–peptide complexes incubated with horseradish
peroxidase-conjugated anti-human β2m conformational-specific polyclonal detection
antibody (Dako P0174) and signal enhancer (Dako Envision). Plates were developed by
colorimetric reaction and absorbances measured at 450 nm using a Victor2 Multilabel ELISA
reader. Based on a standard curve, absorbance measurements were converted to the
concentration of HLA–peptide complexes using a standard curve, and plotted against the
concentration of test peptide used in the assay. The concentration of peptide required to half-
saturate the HLA was determined. At the limiting HLA concentration used, the half-saturation
value approximates the equilibrium dissociation constant value (KD).
2.3.2. Class II Assay—Class II HLA binding assays were performed as previously described
[13]. Briefly, in 96-well plates, non-biotinylated test peptide at 100 μM competed for binding
to purified DR1 (50 nM) against biotinylated influenza hemagglutinin 306-318 standard
peptide (0.1 μM) for 24 hours at 37°C. DR1 molecules were then captured on ELISA plates
using pan anti-Class II antibodies (L243, anti-HLA-DR), developed by addition of streptavidin-
europium and read on a time-resolved fluorescence (TRF) plate reader. Percent inhibition of
biotinylated peptide binding was calculated. Peptides that inhibited competitor by >50% were
considered DRB1*0101 binders.
2.4. Human PBMC T Cell Assay
2.4.1. Study Subjects—Twenty-two healthy adults, ages 18 to 29 years and vaccinated with
Dryvax, were recruited for blood draws at the Saint Louis University Center for Vaccine
Development. Donors were vaccinated between two and three years before blood draws. Donor
HLA types (Class I and II) were determined using One Lambda Micro SSPTM High Resolution
HLA class I and II kits at the Hartford Hospital Transplant Immunology Laboratory. Human
subject studies were performed in accordance with NIH regulations and with the approval of
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the Independent Review Consulting (EpiVax) and Saint Louis University institutional review
boards.
2.4.2. PBMC Isolation and Culture—PBMCs were isolated from whole blood by
centrifugation over a Ficoll cushion. PBMCs were seeded in 12-well tissue culture plates at
10×106 cells/well and stimulated with pools of Class I or Class II peptides in RPMI
supplemented with 10% human AB serum, L-glutamine, gentamicin (Invitrogen), at 37°C
under a 5% CO2 atmosphere. 10 U/mL IL-2 and 20 ng/mL IL-7 (R&D Systems) were added
to each of the wells. Cells were fed every 2 days by half media replacement containing the
same concentration of cytokines. Seven to twenty days post-stimulation, PBMCs were
collected and washed in preparation for antigen re-stimulation to measure cytokine secretion
measurements by enzyme-linked immunospot (ELISpot) assay.
2.4.3. ELISpot Assay—Interferon-gamma ELISpot assays were performed using kits
purchased from Mabtech and performed according to the manufacturer's specifications.
Individual target peptides were added at 10 μg/mL to triplicate wells containing 250,000
PBMCs (in RPMI1640 with 10% human AB serum) and incubated for twenty to forty-eight
hours at 37°C under a 5% CO2 atmosphere. Triplicate wells were plated with
phytohemagglutinin (PHA; 10 μg/mL) and CEF peptide pool (2 μg/mL) as positive controls
and six wells with no peptide were used for background determination. Results were recorded
by ZellNet Consulting, Inc. using a Zeiss high resolution automated ELISpot reader system
and companion KS ELISpot software. In general, responses are considered positive if the
number of spots is at least two times background and greater than 20 spots per one million
cells over background (1 response over background per 50,000 PBMCs). Results are recorded
as the average number of spots over background and adjusted to spots per one million cells
seeded.
3. Results
3.1. In silico epitope mapping
3.1.1. Class I HLA—1,472 open reading frames from 4 vaccinia and 3 variola virus genomes
were computationally screened for conserved Class I MHC epitopes using EpiMatrix (see
Methods for details). First, each protein sequence was parsed into 9-mer and 10-mer sequences,
each overlapping the next by 8 or 9 amino acids, respectively, for a total of 369,394 9-mers
and 367,922 10-mers. Using Conservatrix to discover unique, identical peptides conserved
across all vaccinia and variola strains, we narrowed down the Class I smallpox immunome to
27,158 9-mers and 26,287 10-mers. Each of these peptides was then scored for Class I HLA
motif matches to the A*0101, A*0201, A*0301, A*2402, B*0702 and B*4403 alleles. More
than 1000 EpiMatrix hits (Z-score > 1.64; top 5% of scores) per allele were discovered (data
not shown). The top 100 hits for each allele were subject to a BLAST search against the human
genome to exclude epitopes that may be recognized as self (with a cutoff of no more than 7
identities in a 9-mer sequence), and the top 40 A2 and 20 B7 peptides in a list of ascending
human homology were selected for experimental validation (Figures 2 and 3).
3.1.2. Class II HLA—Two strategies to identify conserved and immunogenic Class II MHC
epitopes were pursued to maximize the likelihood of discovering protective vaccine
immunogens. First, an ORF-by-ORF sequence comparison was performed with the
Copenhagen vaccinia strain selected as the standard for alignment because it contains the most
ORFs of all the strains under consideration. 107 of the 262 ORFs in Vaccinia Copenhagen had
matching ORFs in all six alternate strains with at least 80% identity within the first 200 amino
acids. These ORFs in Vaccinia Copenhagen were computationally screened using EpiMatrix
and ClustiMer to identify epitope dense regions containing sequences predicted to bind
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multiple Class II HLA alleles (DRB1*0101, *0301, *0401, *0701, *1101, *1301 and *1501).
272 epitope clusters were identified, each bearing at least 90% sequence identity across all
seven strains and a cluster score of 15 or above. The sequences were then analyzed by the
BLAST algorithm for human homology. Epitope clusters were ranked first by lowest human
homology with no more than 7 matches in a 9-mer frame accepted, and then by cluster score.
The top 24 epitope clusters were selected for in vitro confirmation (Figure 4). In addition, a
25th cluster was selected for maximal potential immunogenicity, regardless of human
homology.
In a second, separate computational screen, ORFs excluded from the investigation above were
analyzed using Conservatrix to find identical 9-mers in at least six strains, where minimally
three were vaccinia-derived and two variola. 5,781 peptides were discovered, each then scored
for binding affinity to a panel of 8 HLA Class II alleles (see above) using EpiMatrix. 786 unique
9-mers were EpiMatrix hits and subsequently input into the EpiAssembler algorithm to identify
sets of overlapping, conserved and promiscuous epitopes, termed immunogenic consensus
sequence” (ICS) T helper epitopes. 74 ICS with cluster scores greater than 15 were identified
and analyzed for human homology using BLAST. Epitope clusters were ranked first by lowest
human homology, as above, and then by cluster score. The top 25 ICS were selected for in
vitro validation (Figure 4).
3.2. In vitro validation of computational predictions
3.2.1. Class I HLA binding assay—EpiMatrix-predicted epitopes were assessed for their
HLA binding potential in binding assays using soluble HLA. Affinities of HLA*A2 and *B7
epitope peptides for their respective HLA were assessed. We found that 100% of the 40 selected
A2 epitopes identified by EpiMatrix bound A2 (Figures 2 and 5). 31 bound with very high
affinity (1-5 nM KD), 4 with high affinity (6-25 nM KD) and 5 at moderate affinity (26-500
nM KD). Of 20 B7 peptides assayed, 14 (70%) bound B7, 2 with very high affinity, 2 with high
affinity, and 10 with moderate affinity (Figures 3 and 5).
3.2.2. Class II HLA binding assay—Class II epitopes, at a peptide concentration of 100
μM, were screened for binding HLA DRB1*0101 in a competition binding assay using soluble
HLA. Percent inhibition of competitor peptide was used to estimate test peptide affinity. 21 of
50 peptides bound with high affinity (75%-100% inhibition), 2 peptides with moderate
(50%-75% inhibition) and 5 peptides with weak affinity (30%-50%). In total, 28/50 (56%) of
peptides tested bound DR1, as expected of a set of sequences that were predicted to cover a
HLA diverse population, not only DRB1*0101 carriers.
3.3. Ex vivo validation of computational predictions
We validated EpiMatrix-predicted epitopes in measurements of antigen-specific T-cell
responses in 22 human subjects, ages 18-29 years old, who received Dryvax 2 to 3 years before
blood draw. PBMCs were stimulated with pools of smallpox epitopes for 7-20 days and re-
stimulated with individual epitopes and epitope pools in an IFNγ ELISpot assay for 20-48
hours. Response frequency among subjects ranged from 10 to 100% for individual Class II
epitopes. Responses were observed to 41 of 50 (82%) Class II epitopes, with an average of
36% positive responses per subject (Figure 6 and Figure 7, top). All subjects exhibited a robust
response to pooled Class II peptides. Responses plotted according to gene expression
temporality [14,15] reveal no preponderance of T-cell reactivity in a single group of antigens.
For Class I epitopes, antigenicity was detected for 17 of 40 (43%) HLA-A*0201 (Figure 7,
bottom left) and 5 of 20 (25%) B*0702 epitopes (Figure 7, bottom right). Per subject, responses
to A2 epitopes averaged 7% and to B7 epitopes 10%.
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4. Discussion
Using immunoinformatics methods, we scanned vaccinia- and variola-conserved sequences
for HLA Class I and Class II epitopes and then validated the predictions in HLA binding assays
and in humans vaccinated with Dryvax. Our approach to epitope prediction was to discover
the intersection of vaccinia and variola genome sequences that give rise to CD8 and CD4 T
cell-mediated protection against variola as conferred by vaccination with vaccinia. CD8
responses play an important role in containing orthopoxvirus infections and may be a critical
correlate of protection after re-exposure [16,17]. CD4 responses are critical for robust CD8 T
cell proliferation and function and for their differentiation into memory cells in vaccinia
infection [18,19]. Moreover, CD4 responses provide required help to B cells to produce
antibodies that are necessary and sufficient to protect against orthopoxvirus challenge [20].
Hence, we set out to discover potential HLA Class I and Class II variola/vaccinia protective
determinants using computational methods as a high throughput method for scanning large
orthopoxvirus genomes without bias to time of expression or protein function.
4.1. CD4+ T-cell epitopes
We identified 50 HLA Class II epitopes conserved in vaccinia and variola genomes. Half were
predicted with a requirement that all epitopes be conserved in all genomes analyzed and the
other half with the more relaxed requirement that sequences be conserved in at least 3 vaccinia
and 2 variola genomes only out of a total of seven genomes analyzed. We discovered that >80%
of the epitopes were antigenic, with multiple responses observed in all Dryvax vaccinees tested,
illustrating the effectiveness of a predictive approach. Unexpectedly, we found that, with the
exception of the Tian Tian strain, the ICS sequences were more highly conserved, contained
more EpiMatrix hits and produced greater numbers of spot forming cells in interferon-gamma
ELISpot assays than the sequences derived from the more traditional alignment based-
approach. Higher ELISpot numbers may be attributed to the relatively higher concentration of
high scoring 9-mers in the ICS epitopes, to greater sequence conservation or to both factors.
In two related studies, Koelle and co-workers used a non-predictive, experimental screen to
identify CD4+ T cell-antigenic open reading frames and/or protein fragments in the vaccinia
proteome [21,22]. As in those studies, we observed a broad CD4+ T cell response to vaccinia
antigens expressed both early and late in infection, with a majority of the responses to proteins
expressed at the early stage. Because the predictive approach triages sequences for ex vivo
validation, only 29 open reading frames are represented by the selected Class II promiscuous
epitopes in this study. Among these 29, 23 (79%) were observed by Koelle and co-workers to
be antigenic. Considering that the predictive approach significantly limits the part of an open
reading frame that is used to measure antigenicity, this finding illustrates the advantage
immunoinformatics provides for rapidly identifying antigenic open reading frames and
focusing in on a segment that is immunoreactive. Notably, only one of these open reading
frames (L4R) is recognized by 100% of subjects in the non-predictive study, whereas here, 3
of 16 subjects (19%) responded to 4020_II_L4R. While the predictive method is useful for
selecting immunogenic proteins, it is important to note that a single epitope from a highly
immunogenic protein will not necessarily be recognized by all individuals tested. Differences
in the frequency of recognition of a single epitope versus the large protein sequences evaluated
by Koelle and co-workers are possibly due to the limited number of L4R epitope sequences
assayed in the present study, the limited number of subjects in the studies (5 in [21], 12 in
[22], 16 here), the HLA types of the subjects, or differences in the methods used for measuring
antigenicity (proliferation vs. ELISpot).
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4.2. CD8+ T-cell epitopes
We selected 40 A2 and 20 B7 supertype epitopes conserved in the vaccinia and variola genomes
using immune-informatics methods and evaluated them for T cell reactivity ex vivo. Of the 60
epitopes tested, 17 A2 epitopes and 5 B7 epitopes elicited IFN-gamma responses in ex vivo
ELISpot; thus, one in three predicted sequences was confirmed. Only one of these 22 Class I
restricted antigenic epitopes, 5019_A2_I8R, has been reported beforehand [23]. This is
especially noteworthy as several published reports identify A2 vaccinia epitopes [23,24,25,
26]. Particularly, Sette and co-workers performed an extensive study of HLA Class I restricted
vaccinia responses using immuno-informatics methods [24]. Starting with a list of
approximately 2000 A2 and B7 supertype epitopes, 14 A2 and 5 B7 epitopes were found to be
antigenic in Dryvax vaccinees, a ratio of roughly one in 100. None of these epitopes are
identical to the sequences reported here, although two are found in common open reading
frames (E2L, A2; J6R, B7). In a study similar in design, Kazura and co-workers reported 6
new A2 epitopes reactive in persons vaccinated against smallpox. Two are common to protein
antigens reported here (G1L, I8R) and one is identical in sequence, as mentioned above. Factors
that may have contributed to a lack of concordance between these studies include the different
epitope prediction tools used by each group and the limited numbers of subjects sampled.
Nevertheless, like the previously published studies, the breadth of vaccinia-induced immune
response is shown here by ex vivo responses for epitopes derived from 18 different open reading
frames. In addition, we note that the number of epitopes recognized in this study is far fewer
than we observed in previous epitope mapping studies of HIV using EpiMatrix [27]. This may
be a natural outcome of the larger size of the genome, compared to the genome of HIV, which
gives rise to more complex CD8+ T-cell epitope hierarchies [28]. Alternatively, class I epitopes
may not be as critical for protection from poxviruses as previously believed. We plan to
evaluate the relative contributions of class I and class II epitopes to protection from vaccinia
in a challenge study.
4.3. Future studies
The broader goal of this study is to identify epitopes for incorporation into a new smallpox
vaccine that is safer than previously licensed smallpox vaccines. The use of epitopes overcomes
potential safety concerns associated with vaccinating with live vaccinia virus. In addition,
multiple epitopes derived from more than one antigen can be packaged into a relatively small
delivery vehicle. Furthermore, epitope-based vaccines appear to be capable of inducing more
potent responses than whole protein vaccines [29], and they sidestep the propensity for the
immune system to focus on a single immunodominant epitope by simultaneously targeting
multiple dominant and subdominant epitopes [30,31]. This latter feature is particularly
significant because of the great breadth of the antiviral response [21,22,32]. It should be noted
that the field of immuno-informatics is new, and few epitope-driven vaccines for infectious
pathogens have reached the stage of efficacy trials in humans, although several have been
shown to be effective in animal models.
In summary, we are in the process of developing an epitope-based vaccine based on intersecting
sets of epitopes derived from the variola and the vaccinia genomes; this article describes our
progress along the pathway to that goal. We believe that our immunoinformatics-driven
smallpox vaccine development approach may have several advantages over other approaches:
(1) rapidity (the mapping of epitopes and confirmation using human PBMC was accomplished
in less than 18 months); (2) safety (the entire protein is not used, thus the recipient is not exposed
to live vaccinia virus, which may be associated with side effects); and (3) broad
immunogenicity (delivery of multiple epitopes, derived from multiple proteins, recognized in
the context of many different MHC). We also believe that the methods described here, which
will lead to the development of a multi-epitope smallpox vaccine, may be a step in the right
direction for the development of a range of safer, more effective biodefense vaccines.
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Figure 1.
In silico approach to identification of smallpox vaccine candidates. Immunoinformatics tools
identify potential T-cell epitopes from large viral genome datasets, such as variola and the
related vaccine strain vaccinia. Here, informatics methods were used to delineate the
intersection of vaccinia and variola immunogenic epitope sets, which contain sequences that
provide T cell-mediated protection against variola. Conserved sequences among 3 variola and
4 vaccinia genomes were assessed for immunogenic potential using the T-cell epitope mapping
algorithm EpiMatrix. We selected 110 epitopes for vaccine design, of which 50 were
promiscuous Class II HLA epitopes, 40 were Class I HLA A2 and 20 were Class I B7. 60%
of the epitopes were derived from regulatory factors, 24% from hypothetical and unknown
proteins and16% from structural proteins.
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Figure 2.
Characteristics of selected A2 peptides. The peptide IDs and amino acid sequences are shown
followed by their gene expression temporality. Here, “early and late” refers to early and late
post-replication phase expression. The accession numbers for the corresponding ORFs within
3 variola and 4 vaccinia genomes are listed. In addition, the EpiMatrix A2 Z-score and KD
(nM) are presented.
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Figure 3.
Characteristics of selected B7 peptides. The peptide IDs and amino acid sequences are shown
followed by their gene expression temporality. Here, “early and late” refers to early and late
post-replication phase expression. The accession numbers for the corresponding ORFs within
3 variola and 4 vaccinia genomes are listed. In addition, the EpiMatrix HLA B7 Z-score and
KD (nM) are shown.
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Figure 4.
Characteristics of selected Class II peptides. The peptide IDs and amino acid sequences are
shown followed by their gene expression temporality. Here “early and late” refers to early and
late post-replication phase expression. The accession numbers for the corresponding ORFs
within 3 variola and 4 vaccinia genomes are listed. The top 25 epitopes were discovered in the
first Class II epitope screen and the bottom 25 in the second (see Results). In addition, the
EpiMatrix Class II cluster score, the cluster sum of DRB1*0101 scores and % inhibition of
competitor peptide binding to DRB1*0101 at 100 μM epitope peptide are shown. Asterisks
refer to peptides that were not assayed for binding.
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Figure 5.
In vitro validation of computationally identified epitopes. Predicted epitopes were assayed for
binding to individual HLA alleles, A2, B7 and DRB1*0101. The percent of predicted epitopes
that bound these alleles is shown. Class II epitopes were selected for predicted binding to
multiple HLA alleles (see Methods), not solely to DRB1*0101.
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Figure 6.
Ex vivo validation of computationally identified Class II HLA epitopes. Predicted epitopes
were assayed for T cell reactivity by IFN-γ ELISpot assay using PBMCs isolated from Dryvax-
vaccinated donors. Epitopes are grouped according to their timing of expression as parts of
whole proteins in the poxvirus life cycle. The “early and late” designation refers to early and
post-replication late expression. The percentage of subjects who responded to individual
epitopes in descending order (bars) and the average spot forming cells per million PBMCs for
each epitope (circles) are illustrated.
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Figure 7.
IFN-γ ELISpot responses to predicted Class I and Class II epitopes in Dryvax vaccinated human
subjects. The numbers of spot forming cells (over background) per million PBMCs that secrete
IFN-γ in response to individual and pooled Class I and Class II epitopes, as well as PHA and
CEF are presented. For simplicity, non-significant results are denoted by n/s and missing data
are omitted (not tested, NT). Significant results are highlighted in black. An ELISpot response
was considered positive if two criteria were met: (1) spot-forming cells per million PBMC
were at least 20 over background; (2) spot-forming cells (SFC) per million PBMC were at least
two-fold over background. Column headers: human subject ID code, average responses and
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percent of subjects responding. Row labels: peptide ID. Epitopes are grouped according to their
timing of expression as parts of whole proteins in the poxvirus life cycle.
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